Close menu




Vidac Pharma Holding PLC

Photo credits: pixabay.com

Commented by Fabian Lorenz on November 18th, 2024 | 07:00 CET

Takeover speculation and momentum: BioNTech, Rheinmetall, Vidac Pharma

  • Biotechnology
  • Biotech
  • Pharma
  • Defense

BioNTech aims to strengthen its cancer-fighting pipeline by acquiring the Chinese biotech firm Biotheus. The Mainz-based company is laying out up to USD 950 million for the company, which specializes in the development of therapies for cancer and autoimmune diseases. This is the latest example of takeovers in the cancer sector. Vidac Pharma, with a market capitalization of just over EUR 30 million, appears to be favorably valued. Analysts share this view, as Vidac is working on a revolutionary cancer therapy. While Vidac's share price jumped in the second half of the year, Rheinmetall consolidated. Will the defense stock be able to break out with the tailwind from Trump?

Read

Commented by André Will-Laudien on November 14th, 2024 | 07:15 CET

The acquisition carousel is gaining momentum! Evotec, Vidac Pharma, BioNTech, and Formycon in focus

  • Pharma
  • Biotechnology
  • Biotech

The biotech sector is in the spotlight again today. Triton's entry into Evotec means that another deal is in the works, and investors should now take notice. Many still remember MorphoSys, where there were short-term gains of up to 400% at the beginning of the year. Before that, the stock had been trading with high volumes. Will Formycon or Vidac Pharma be next on the list? Formycon is now getting significantly more attention because the stock switched to the Prime Standard. Evotec has once again disappointed operationally, yet the value has increased by a good 50% in just two months. Those who analyze carefully can profit again. A sharp analytical eye is worthwhile.

Read

Commented by André Will-Laudien on October 24th, 2024 | 07:30 CEST

Biotech – Are takeovers looming amidst curious prices? Evotec, Bayer, Vidac Pharma and BioNTech in the spotlight

  • Biotechnology
  • Biotech
  • Pharma

The biotech sector is once again in the spotlight. Since the acquisition of MorphoSys at the beginning of the year, the speculation carousel is turning again. Is Evotec next, or maybe Vidac Pharma? The Hamburg-based drug specialist came under fire from short-sellers after the resignation of long-standing CEO Lanthaler, who had shorted over 4% of the capital by mid-September. However, the price stubbornly held above the EUR 5 mark, and yesterday saw a 10% rise to EUR 6.60. What is behind this? Last week, it was Vidac Pharma that surged 300% from a standing start with enormous trading volumes. The thought processes of market participants are evident: interest rates are falling, making refinancing attractive again for upcoming financial investors. We shed light on the key players.

Read

Commented by Stefan Feulner on October 14th, 2024 | 07:00 CEST

Bayer, Vidac Pharma, Evotec – Enormous potential

  • Biotech
  • Biotechnology
  • Pharma

Since the US Federal Reserve cut key interest rates and signaled a continuation of its loose monetary policy, the Nasdaq Biotech Index has been on an upward trajectory and has significantly outperformed the broader market in recent days. The correction of the past few months seems to be over in this sector, and the all-time high from August 2021 is within reach. In addition to rising share prices, the number of acquisitions is also increasing significantly, a sign of the undervaluation of many listed companies.

Read

Commented by Fabian Lorenz on October 9th, 2024 | 07:15 CEST

Biotech comeback and takeover fantasy! BioNTech, Bayer, and Vidac Pharma

  • Biotechnology
  • Biotech
  • Pharma

Money can be made in biotech shares again! However, investors need to look carefully. While Moderna is at a multi-year low, BioNTech and Vidac Pharma have gained over 50% in just a few months. Is there more to come? The chances are good, as both biotech companies have released promising news. Analysts see a tenfold increase in the case of Vidac Pharma, and the focus on the fight against cancer makes the Company a takeover candidate. The cancer specialist would also be a good fit for Bayer and BioNTech, and the share is still cheap. BioNTech is becoming an investment darling again and is focusing on AI. Bayer has yet to make the leap above EUR 30, and analysts are warning about the upcoming quarterly figures.

Read

Commented by André Will-Laudien on September 16th, 2024 | 07:15 CEST

This is unbelievable! 250% with an announcement: Bayer, Vidac Pharma, Evotec, and Valneva

  • Biotechnology
  • Biotech
  • Pharma

The stock market has been rallying week after week, yet the biotech sector stubbornly lags behind. However, with the first interest rate cut in Europe, the path of lower financing options has now also been mapped out for the US. This week, the FED is set to decide on rate cuts, with 87% of capital market experts expecting a total of three cuts by the end of the year. That would be grist to the mill for growth stocks. Vidac Pharma has already gained 50% in 2 months, and Bayer and Evotec will likely follow soon. Valneva is raising EUR 61 million and aims to break even operationally. What is next for the sector?

Read

Commented by Fabian Lorenz on September 11th, 2024 | 07:00 CEST

Multiplication and travel boom! Bayer, TUI, Vidac Pharma

  • Biotechnology
  • Pharma
  • Travel

Vidac Pharma shares have gained over 23% in the past four weeks. Driven by strong study data from the biotech company focused on fighting cancer, analysts even see the potential for multiplication. Such euphoria has been absent at Bayer for some time. However, at least there is positive momentum from the pharmaceuticals division again, which is much needed, as the Leverkusen-based company's pipeline is considered modest. In contrast, business at TUI is booming. Nevertheless, the tourism group's shares have disappointed in the current year. Will a new cruise ship take it towards EUR 10?

Read

Commented by Armin Schulz on September 4th, 2024 | 07:30 CEST

Bayer, Vidac Pharma, BioNTech - Healthcare sector on the verge of a renaissance

  • Biotechnology
  • Biotech
  • Pharma

Promising signs of a renaissance in the healthcare sector have emerged in recent months. Innovative start-ups are driving the digital transformation forward despite a decline in investment, as evidenced by the Digital Health Radar 2024. In Germany, Federal Health Minister Karl Lauterbach has introduced significant legislative reforms by July 2024, such as the introduction of electronic patient records and e-prescriptions. Complemented by increased M&A activity and technological integration through telehealth and AI, experts anticipate significant long-term growth potential despite the challenges faced in 2023. These developments point to a promising future for the healthcare sector. We take a look at three exciting candidates.

Read

Commented by Stefan Feulner on August 28th, 2024 | 07:15 CEST

Siemens Healthineers, Vidac Pharma, Viking Therapeutics - Powerful movements

  • Biotechnology
  • Biotech
  • Pharma
  • Healthcare

After the hype during the COVID-19 pandemic, biotech stocks have lagged behind the broader market, allowing major technology companies to take the lead. Smaller, capital-intensive companies, in particular, have suffered from the high interest rate level. However, this is likely to change soon. On the one hand, monetary policy is expected to be eased, and on the other hand, demographic changes point to a long-term explosion in demand for new medications.

Read

Commented by André Will-Laudien on August 5th, 2024 | 07:00 CEST

In the fight against cancer - 100% performance possible: Bayer, Vidac Pharma, Evotec, BioNTech and CureVac

  • Biotechnology
  • Biotech
  • Pharma

The FED is giving new hope to the Biotech sector with lower interest rates, which are expected to happen as early as September. This is important for the near future, as share prices are lagging dramatically behind the NASDAQ performance in 2024. However, if extensive research can be financed under more favourable conditions, this should also help the stock market prices recover. The business models contain some good news, and selection is now crucial. We assist in selecting attractive stocks and provide entry levels.

Read